Dopaminergic therapy modulates cortical perfusion in Parkinson disease with and without dementia according to arterial spin labeled perfusion magnetic resonance imaging

Medicine (United States)

Volumn 95, Issue 5, 2016, Pages

  Lin, Wei Che ^a   Chen, Pei Chin ^a   Huang, Yung Cheng ^a   Tsai, Nai Wen ^a   Chen, Hsiu Ling ^a   Wang, Hung Chen ^b   Lin, Tsu Kung ^a   Chou, Kun Hsien ^b   Chen, Meng Hsiang ^a   Chen, Yi Wen ^a   Lu, Cheng Hsien ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA; DOPAMINE RECEPTOR STIMULATING AGENT;

ADULT; ANTERIOR CINGULATE; ARTERIAL SPIN LABELED PERFUSION MAGNETIC RESONANCE IMAGING; ARTICLE; BRAIN BLOOD FLOW; BRAIN PERFUSION; CAUDATE NUCLEUS; CEREBELLUM; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICAL PERFUSION; DEMENTIA; DISEASE SEVERITY; FEMALE; FRONTAL LOBE; HUMAN; INFERIOR FRONTAL GYRUS; MALE; MIDDLE AGED; MIDDLE FRONTAL GYRUS; MINI MENTAL STATE EXAMINATION; NUCLEAR MAGNETIC RESONANCE SCANNER; OCCIPITAL LOBE; PARAHIPPOCAMPAL GYRUS; PARIETAL LOBE; PARKINSON DISEASE; PERFUSION WEIGHTED IMAGING; PRECUNEUS; PREFRONTAL CORTEX; PREMOTOR CORTEX; PRIORITY JOURNAL; SPIN LABELING; TEMPORAL LOBE; THALAMUS; UNIFIED PARKINSON DISEASE RATING SCALE; UNITED KINGDOM; VISUAL CORTEX; AGED; BRAIN CIRCULATION; BRAIN CORTEX; CASE CONTROL STUDY; COMPLICATION; DRUG EFFECTS; MAGNETIC RESONANCE ANGIOGRAPHY; PATHOPHYSIOLOGY;

AGED; CASE-CONTROL STUDIES; CEREBRAL CORTEX; CEREBROVASCULAR CIRCULATION; DEMENTIA; DOPAMINE AGENTS; FEMALE; HUMANS; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MIDDLE AGED; PARKINSON DISEASE;

EID: 84958818972     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000002206     Document Type: Article

References (40)

1. Goetz CG, Emre M, Dubois B. Parkinson's disease dementia: definitions, guidelines, and research perspectives in diagnosis. Ann Neurol. 2008;64:S81-S92.
2. Politis M. Neuroimaging in Parkinson disease: from research setting to clinical practice. Nature reviews. Neurology. 2014;10:708-722.
3. Melzer TR, Watts R, MacAskill MR, et al. Arterial spin labelling reveals an abnormal cerebral perfusion pattern in Parkinson's disease. Brain. 2011;134:845-855.
4. Huang C, Tang C, Feigin A, et al. Changes in network activity with the progression of Parkinson's disease. Brain. 2007;130:1834-1846.
5. Herz DM, Haagensen BN, Christensen MS, et al. The acute brain response to levodopa heralds dyskinesias in Parkinson disease. Ann Neurol. 2014;75:829-836.
6. Poletti M, Bonuccelli U. Acute and chronic cognitive effects of levodopa and dopamine agonists on patients with Parkinson's disease: a review. Ther Adv Psychopharmacol. 2013;3:101-113.
7. Kamagata K, Motoi Y, Hori M, et al. Posterior hypoperfusion in Parkinson's disease with and without dementia measured with arterial spin labeling MRI. J Magn Reson Imaging. 2011;33:803-807.
8. Kelly C, de Zubicaray G, Di Martino A, et al. L-dopa modulates functional connectivity in striatal cognitive and motor networks: a double-blind placebo-controlled study. J Neurosci. 2009;29:7364-7378.
9. Kwak Y, Peltier S, Bohnen NI, et al. Altered resting state corticostriatal connectivity in mild to moderate stage Parkinson's disease. Front Syst Neurosci. 2010;4:143.
10. Deibler AR, Pollock JM, Kraft RA, et al. Arterial spin-labeling in routine clinical practice, part 1: technique and artifacts. AJNR Am J Neuroradiol. 2008;29:1228-1234.
11. Mirasol RV, Bokkers RP, Hernandez DA, et al. Assessing reperfusion with whole-brain arterial spin labeling: a noninvasive alternative to gadolinium. Stroke. 2014;45:456-461.
12. Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55:181-184.
13. Hobson DE, Lang AE, Martin WR, et al. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. J Am Med Assoc. 2002;287:455-463.
14. Chou KH, Lin WC, Lee PL, et al. Structural covariance networks of striatum subdivision in patients with Parkinson's disease. Hum Brain Mapp. 2015;36:1567-1584.
15. Folstein MF, Folstein SE, McHugh PR. Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
16. Dai W, Garcia D, de Bazelaire C, et al. Continuous flow-driven inversion for arterial spin labeling using pulsed radio frequency and gradient fields. Magn Reson Med. 2008;60:1488-1497.
17. Smith SM. Fast robust automated brain extraction. Hum Brain Mapp. 2002;17:143-155.
18. Greve DN, Fischl B. Accurate and robust brain image alignment using boundary-based registration. Neuroimage. 2009;48:63-72.
19. Ashburner J. A fast diffeomorphic image registration algorithm. Neuroimage. 2007;38:95-113.
20. Johnson NA, Jahng GH, Weiner MW, et al. Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience. Radiology. 2005;234:851-859.
21. Wang Z, Aguirre GK, Rao H, et al. Empirical optimization of ASL data analysis using an ASL data processing toolbox: ASLtbx. Magn Reson Imaging. 2008;26:261-269.
22. Fernandez-Seara MA, Mengual E, Vidorreta M, et al. Cortical hypoperfusion in Parkinson's disease assessed using arterial spin labeled perfusion MRI. Neuroimage. 2012;59:2743-2750.
23. Borghammer P, Chakravarty M, Jonsdottir KY, et al. Cortical hypometabolism and hypoperfusion in Parkinson's disease is extensive: probably even at early disease stages. Brain Struct Funct. 2010;214:303-317.
24. Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24:197-211.
25. Firbank MJ, Colloby SJ, Burn DJ, et al. Regional cerebral blood flow in Parkinson's disease with and without dementia. Neuroimage. 2003;20:1309-1319.
26. Nagano-Saito A, Washimi Y, Arahata Y, et al. Cerebral atrophy and its relation to cognitive impairment in Parkinson disease. Neurology. 2005;64:224-229.
27. Pan PL, Song W, Shang HF. Voxel-wise meta-analysis of gray matter abnormalities in idiopathic Parkinson's disease. European journal of neurology: the official journal of the European Federation of Neurological Societies. 2012;19:199-206.
28. Wu T, Long X, Zang Y, et al. Regional homogeneity changes in patients with Parkinson's disease. Hum Brain Mapp. 2009;30:1502-1510.
29. Hammond C, Bergman H, Brown P. Pathological synchronization in Parkinson's disease: networks, models and treatments. Trends Neurosci. 2007;30:357-364.
30. Silberstein P, Pogosyan A, Kuhn AA, et al. Cortico-cortical coupling in Parkinson's disease and its modulation by therapy. Brain. 2005;128:1277-1291.
31. Lee EY, Eslinger PJ, Du G, et al. Olfactory-related cortical atrophy is associated with olfactory dysfunction in Parkinson's disease. Mov Disord. 2014;29:1205-1208.
32. Gonzalez-Redondo R, Garcia-Garcia D, Clavero P, et al. Grey matter hypometabolism and atrophy in Parkinson's disease with cognitive impairment: a two-step process. Brain. 2014;137:2356-2367.
33. Ito K, Nagano-Saito A, Kato T, et al. Striatal and extrastriatal dysfunction in Parkinson's disease with dementia: a 6-[18F]fluoro-Ldopa PET study. Brain. 2002;125:1358-1365.
34. Wu T, Hallett M. The cerebellum in Parkinson's disease. Brain. 2013;136:696-709.
35. Block G, Liss C, Reines S, et al. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group. Eur Neurol. 1997;37:23-27.
36. Maggio R, Barbier P, Corsini GU. Apomorphine continuous stimulation in Parkinson's disease: receptor desensitization as a possible mechanism of reduced motor response. J Neural Transm Suppl. 1995;45:133-136.
37. Olanow CW, Obeso JA. Levodopa toxicity and Parkinson disease: still a need for equipoise. Neurology. 2011;77:1416-1417.
38. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol. 2003;54:93-101.
39. Parkinson Study G. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. J Am Med Assoc. 2002;287:1653-1661.
40. Bhatia K, Brooks DJ, Burn DJ, et al. Guidelines for the management of Parkinson's disease. The Parkinson's Disease Consensus Working Group. Hosp Med. 1998;59:469-480.